Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$14.29MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc William Elia
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 122
- Beta
- 0.71
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -3.35
Financials
Revenue
$14.29M+531.0%Net Income
$-44.39MEBITDA
$-45.74MFree Cash Flow
$-43.52MEPS (diluted)
$-0.14Shares Outstanding (diluted)
320.44M+1407.9%Operating Expenses
$58.83MCash & Debt
$160.08MReturn of Capital
$0.00Revenue by Segment (annual)
$53.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $53.43M | $-52.49M | $-0.30 |
| 2024 | $25.38M | $-169.93M | $-1.43 |
| 2023 | $0.00 | $-198.64M | $-1.81 |
| 2022 | $0.00 | $-241.32M | $-2.17 |
| 2021 | $0.00 | $-226.79M | $-2.11 |
| 2020 | $0.00 | $-111.98M | $-0.59 |
Valuation
IVVDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-66.67%Social Signal Score
Mentions (10)
- Newsglobenewswire.com·1d ago·Negative
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to th…
View source ↗ - Newsmarketbeat.com·1d ago·Negative
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration.
View source ↗ - Newsbenzinga.com·6d ago·Neutral
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.
View source ↗ - Newsseekingalpha.com·6d ago·Neutral
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
View source ↗ - Newsglobenewswire.com·7d ago·Negative
…uperior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine C…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Invivyd to Participate in Upcoming September Investor Conferences NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·33d ago·Negative
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company. He will serve as Chairman and CEO of Invivyd going forward.
View source ↗ - Newszacks.com·53d ago·Negative
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.11 per share
Typical surprise -31.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.14 vs $-0.11miss
- Thu, May 14$-0.13 vs $-0.08miss
- Thu, Mar 5$0.02 vs $-0.06beat
- Thu, Nov 6$-0.06 vs $-0.05miss
- Thu, Aug 14$-0.12 vs $-0.04miss
- Thu, May 15$-0.14 vs $-0.04miss
Estimates and results for IVVD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IVVD officers and directors.
- Bought
- $125k
- Sold
- $830k
1 trade
33 trades
- Lee Timothy Edwardsold
- Green Juliesold
- Duke William E.sold
- Andersen Jillsold
- Allen Robert D. Iiisold
- Lee Timothy Edwardsold
- Green Juliesold
- Duke William E.sold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IVVD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.